Inflammasome Therapeutics today announced that additional analyses from its Phase 2 study of Kamuvudine K8 in geographic atrophy will be presented at the American Academy of Ophthalmology (AAO) Retina ...
Kensington, MD, USA, and Munich/Martinsried, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Data presented at EURETINA 2026 ...
Studies highlighted rapid and durable redness relief with a novel formulation of LUMIFY ® redness reliever eye drops containing hyaluronic acid ...
Lyrfigtu (lirafugratinib) is approved for previously treated, unresectable, or metastatic FGFR2-altered cholangiocarcinoma based on data from the ReFocus trial.
Lyrfigtu demonstrated a confirmed ORR of 46% and mDOR of 11.8 months, with a predictable and manageable safety profile FORT LEE, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a ...
Researchers evaluated whether contrast sensitivity testing can detect early retinal toxicity in patients taking hydroxychloroquine or chloroquine. Contrast sensitivity testing does not detect ...
Tamoxifen-induced retinopathy is well recognized and frequently reported in clinical practice. By contrast, ocular adverse events associated with the structurally similar agent toremifene remain ...
Color vision allows primates to distinguish objects based on subtle differences in light wavelength. In humans and Old World primates, this ability depends on three types of cone cells, red, green, ...
A 49-year-old Black woman with a history of systemic lupus erythematosus (SLE) presented for a scheduled evaluation for hydroxychloroquine (HCQ) ophthalmic monitoring. She was diagnosed with SLE in ...
Novel systemic anticancer therapies, including immune checkpoint inhibitors (ICIs), antibody-drug conjugates (ADCs), bispecific antibodies, and next-generation targeted agents, have improved survival, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results